StockpollyBeta
Get App
Popularity #3,518
IFRX · NASDAQ · Biotechnology

InflaRx (IFRX)

Develops C5a-pathway medicines centered on oral izicopan for inflammatory and renal diseases.

$2.02
vs last close−0.06 (−3.13%)

In millions of USD, except per-share figures · converted from EUR at the latest rate

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue000003030600
Gross profit00000−30−30−600
12151417188151211988
Research & development89811138887655
556455754343
Selling & marketing20202−1211−200
General & administrative354436643543
Other expenses−11010−5−1−1−1000
Operating income−13−15−14−18−17−11−15−15−11−15−8−8
4−333−255−2−332−4
Interest income111111110001
Interest expense000000000000
Other non-operating income−43−3−32−5−523−3−24
Income before tax−8−18−11−14−20−6−9−16−14−12−6−12
Income tax expense000000000000
Net income from continuing operations−8−18−11−14−20−6−9−16−14−12−6−12
Other adjustments000−100000000
Net income−8−18−11−16−20−6−9−16−14−12−6−12
EPS, basic−$0.15−$0.30−$0.18−$0.27−$0.34−$0.10−$0.15−$0.24−$0.21−$0.16−$0.09−$0.10
EPS, diluted−$0.15−$0.30−$0.18−$0.27−$0.34−$0.10−$0.15−$0.24−$0.21−$0.16−$0.09−$0.10
Weighted average shares, basic5959595959596368686772118
Weighted average shares, diluted5959595959596368686772118
EBITDA−8−18−11−14−20−6−9−16−14−12−6−12
Depreciation & amortization000000000000
EBIT−8−18−11−14−20−6−9−16−14−12−6−12